Medicus Pharma (MDCX) director receives grant of 50,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Medicus Pharma Ltd. director Ashton William received a grant of stock options as part of his compensation. He was awarded options covering 50,000 common shares at an exercise price of $0.3600 per share. The options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year, ending on June 3, 2027. These options expire on June 3, 2031, and following this grant he holds options on 50,000 shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ashton William
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 50,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 50,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 50,000 options
Exercise price: $0.3600 per share
Underlying shares: 50,000 common shares
+3 more
6 metrics
Options granted
50,000 options
Grant to director on June 3, 2026
Exercise price
$0.3600 per share
Stock option strike price
Underlying shares
50,000 common shares
Shares underlying granted options
Expiration date
June 3, 2031
Option term end date
Shares following transaction
50,000 options
Total options held directly after grant
Vesting schedule
4 quarterly installments over 1 year
From June 3, 2026 grant date
Key Terms
Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vest quarterly, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "0.3600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest quarterly financial
"The option is scheduled to vest quarterly in four equal installments over one year."
expiration date financial
"expiration_date: "2031-06-03T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transaction did Medicus Pharma (MDCX) report for Ashton William?
Medicus Pharma reported that director Ashton William received a grant of stock options for 50,000 common shares. The award was made on June 3, 2026, as compensation and gives him the right to buy shares at a fixed exercise price in the future.
How many Medicus Pharma stock options were granted to Ashton William?
Ashton William was granted stock options covering 50,000 common shares of Medicus Pharma. This award represents his entire reported option position in this filing, with all 50,000 options held directly following the grant as part of his director compensation package.
What is the exercise price and expiration date of Ashton William’s Medicus Pharma options?
The stock options granted to Ashton William have an exercise price of $0.3600 per common share and expire on June 3, 2031. This means he can choose to purchase shares at $0.3600 anytime before that expiration date, subject to vesting.
How do Ashton William’s Medicus Pharma options vest over time?
The options granted to Ashton William vest quarterly in four equal installments over one year. The grant was made on June 3, 2026, so vesting occurs in four quarterly tranches through June 3, 2027, aligning vesting with continued service as a director.